News

Annual General Meeting (AGM) Statement

Proteome Sciences is pleased to announce that the Company has secured a contract from a major US academic group. 

The Company has received notification from Vulpes Investment Management Pte Ltd ("Vulpes") that on 22 April 2022 it purchased 183,812 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 4p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 67,475,006 Ordinary Shares, equivalent to 22.86% of Proteome Sciences' total issued share capital.

The Company has received notification from Vulpes Investment Management Pte Ltd ("Vulpes") that on 19 April 2022 it purchased 1,465,000 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 4p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 67,291,194 Ordinary Shares, equivalent to 22.80% of Proteome Sciences' total issued share capital.

Proteome Sciences plc is pleased to announce that Chief Executive Officer, Dr Mariola Soehngen, will provide a live presentation relating to the Company’s results for the year ended 31 December 2021 via the Investor Meet Company platform on 28 April 2021 at 10.30am BST.

The Company has been notified that the shareholding of Vulpes Life Sciences Fund ("Vulpes") remains unchanged at 65,826,194 ordinary shares, representing 22.3 per cent of the share capital, but that the holding has been transferred to a new custodian to hold the shares on Vulpes’ behalf.

The Company is pleased to announce its audited results for the year ended 31 December 2021.

On 3 July 2018, the Company entered into a £1 million loan facility with Vulpes Investment Management Private Limited ("VIM") (the “Loan”).  The Directors of Proteome Sciences are now pleased to announce that the Loan has been amended such that the Loan (of which £700,000 is currently drawn) and all accrued interest is now repayable on 30 June 2023 (previously 1 May 2022) (the “Loan Amendment”). 

The Directors of Proteome Sciences look forward to updating shareholders on the Company’s performance, and on the outlook for 2022, at the time of announcing the 2021 full year results which are scheduled for announcement on Thursday, 31 March 2022.